ATE513848T1 - Phl p 5a-derivate mit reduzierter allergenität und erhaltener t-zellreaktivität - Google Patents

Phl p 5a-derivate mit reduzierter allergenität und erhaltener t-zellreaktivität

Info

Publication number
ATE513848T1
ATE513848T1 AT04739147T AT04739147T ATE513848T1 AT E513848 T1 ATE513848 T1 AT E513848T1 AT 04739147 T AT04739147 T AT 04739147T AT 04739147 T AT04739147 T AT 04739147T AT E513848 T1 ATE513848 T1 AT E513848T1
Authority
AT
Austria
Prior art keywords
phl
preserved
derivatives
reactivity
cell reactivity
Prior art date
Application number
AT04739147T
Other languages
German (de)
English (en)
Inventor
Martin Wald
Oliver Cromwell
Andreas Nandy
Helga Kahlert
Bernhard Weber
Helmut Fiebig
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE513848T1 publication Critical patent/ATE513848T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04739147T 2003-06-04 2004-05-06 Phl p 5a-derivate mit reduzierter allergenität und erhaltener t-zellreaktivität ATE513848T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10325508 2003-06-04
PCT/EP2004/004848 WO2004108758A1 (de) 2003-06-04 2004-05-06 Phl p 5a-derivate mit reduzierter allergenität und erhaltener t-zellreaktivität

Publications (1)

Publication Number Publication Date
ATE513848T1 true ATE513848T1 (de) 2011-07-15

Family

ID=33494849

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04739147T ATE513848T1 (de) 2003-06-04 2004-05-06 Phl p 5a-derivate mit reduzierter allergenität und erhaltener t-zellreaktivität

Country Status (13)

Country Link
US (3) US8628946B2 (enExample)
EP (3) EP2272863B1 (enExample)
JP (2) JP4782671B2 (enExample)
CN (1) CN1798763B (enExample)
AT (1) ATE513848T1 (enExample)
AU (1) AU2004245184B2 (enExample)
BR (1) BRPI0410908A (enExample)
CA (1) CA2528053C (enExample)
ES (3) ES2434720T3 (enExample)
PL (2) PL2272863T3 (enExample)
PT (3) PT2287180E (enExample)
RU (1) RU2368620C2 (enExample)
WO (1) WO2004108758A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR779201A0 (en) 2001-09-20 2001-10-11 University Of Melbourne, The Immunotherapeutic and immunoprophylactic reagents
PT2287180E (pt) * 2003-06-04 2013-10-31 Merck Patent Gmbh Derivados de lol p 5 com alergenicidade reduzida e reatividade mantida com as células t
AT503690A1 (de) * 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
US9975932B2 (en) 2010-01-14 2018-05-22 Merck Patent Gmbh Variants of group 5 allergens of the true grasses having reduced allergeneity due to mutagenesis of proline residues
KR20240055084A (ko) 2021-09-13 2024-04-26 라이프 테크놀로지스 코포레이션 유전자 편집 도구

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736362A (en) * 1990-10-26 1998-04-07 The University Of Melbourne Ryegrass pollen allergen
DE19713001A1 (de) 1997-03-27 1998-10-01 Merck Patent Gmbh Graminaenpollenallergenmutanten zur spezifischen Immuntherapie, deren Herstellung und Verwendung
DE19918682A1 (de) 1999-04-23 2000-10-26 Merck Patent Gmbh DNA-Sequenz und rekombinante Herstellung eines Graminaen-Allergens
IT1318692B1 (it) 2000-09-12 2003-08-27 Consiglio Nazionale Ricerche Varianti di proteine allergeniche di phleum pratense.
DE60136653D1 (de) * 2000-11-16 2009-01-02 Alk Abello As Mutante allergene
AUPR779201A0 (en) * 2001-09-20 2001-10-11 University Of Melbourne, The Immunotherapeutic and immunoprophylactic reagents
PT2287180E (pt) * 2003-06-04 2013-10-31 Merck Patent Gmbh Derivados de lol p 5 com alergenicidade reduzida e reatividade mantida com as células t

Also Published As

Publication number Publication date
CA2528053C (en) 2014-08-12
JP2007536893A (ja) 2007-12-20
ES2434720T3 (es) 2013-12-17
PL2287180T3 (pl) 2013-12-31
JP4782671B2 (ja) 2011-09-28
EP2272863A1 (de) 2011-01-12
CA2528053A1 (en) 2004-12-16
ES2397778T3 (es) 2013-03-11
PT2272863E (pt) 2013-01-30
AU2004245184A1 (en) 2004-12-16
WO2004108758A1 (de) 2004-12-16
AU2004245184B2 (en) 2011-03-24
PL2272863T3 (pl) 2013-03-29
EP2287180A1 (de) 2011-02-23
US20160207967A1 (en) 2016-07-21
US8628946B2 (en) 2014-01-14
US20140255434A1 (en) 2014-09-11
ES2367633T3 (es) 2011-11-07
RU2005141524A (ru) 2006-09-10
JP2011041566A (ja) 2011-03-03
PT1629006E (pt) 2011-09-28
EP2287180B9 (de) 2013-11-06
EP1629006B1 (de) 2011-06-22
BRPI0410908A (pt) 2006-06-27
EP1629006A1 (de) 2006-03-01
JP5363441B2 (ja) 2013-12-11
CN1798763B (zh) 2010-05-26
US20100158955A1 (en) 2010-06-24
PT2287180E (pt) 2013-10-31
EP2287180B1 (de) 2013-08-07
RU2368620C2 (ru) 2009-09-27
US9522938B2 (en) 2016-12-20
EP2272863B1 (de) 2012-10-31
CN1798763A (zh) 2006-07-05

Similar Documents

Publication Publication Date Title
KR102556485B1 (ko) 신규 면역원성 펩티드
JP2023515386A (ja) 制御性ｔ細胞エピトープと脱寛容化ｓａｒｓ－ｃｏｖ－２抗原
EP1725575B1 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
WO2009154995A3 (en) Interleukin 10 receptor (il-10r) antibodies and methods of use
CY1109715T1 (el) IL-1β ΔΕΣΜΕΥΤΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ΚΑΙ ΘΡΑΥΣΜΑΤΑ ΑΥΤΩΝ
MX2007003402A (es) Composicion inmunogena para su uso en vacunacion contra estafilococos.
EP2562183A8 (en) Novel immunogenic epitopes for immunotherapy
NO20063026L (no) Antistoffer
US20110150920A1 (en) Allergy Vaccines Containing Hybrid Polypeptides
BRPI0412799A (pt) imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura
WO2008057235A3 (en) Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes
US9963489B2 (en) House dust mite allergen
DE60037900D1 (de) Chlamydia antigene und entsprechende dna-fragmente und ihre verwendungen
ATE513848T1 (de) Phl p 5a-derivate mit reduzierter allergenität und erhaltener t-zellreaktivität
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
ATE432944T1 (de) Varianten der gruppe 1-allergene aus poaceae mit reduzierter allergenität und erhaltener t- zellreaktivität
WO2003093416A3 (en) Protective antigens for the control of ixodes species infestations
PL400683A1 (pl) Sekwencja DNA oraz sposób otrzymywania rekombinowanego alergenu pylku traw PHL P4
TWI804553B (zh) 用於ＩｇＥ介導過敏性疾病治療之靶向膜鑲嵌型ＩｇＥ的胜肽免疫原及其劑型
ATE399794T1 (de) Modifizierter granulozyten stimulierender factor (g-csf) mit verringerter immunogenität
Morrison et al. Contribution of advances in immunology to vaccine development
CA2452695A1 (en) Novel surface exposed immunoglobulin d-binding protein from moraxella catarrhalis
BRPI0604365A (pt) polipeptìdeo isolado, composição de vacina anti-carrapato de múltiplas espécies, e, uso dos mesmos
Ågren et al. A genetically engineered non-toxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit
ATE547530T1 (de) Rekombinante vektoren auf der grundlage des modifizierten vacciniavirus ankara (mva) als impfstoffe gegen leishmaniase